175 related articles for article (PubMed ID: 27861244)
1. Effects of risk assessment and management programme for hypertension on clinical outcomes and cardiovascular disease risks after 12 months: a population-based matched cohort study.
Yu EY; Wan EY; Wong CK; Chan AK; Chan KH; Ho SY; Kwok RL; Lam CL
J Hypertens; 2017 Mar; 35(3):627-636. PubMed ID: 27861244
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the quality of care of a multi-disciplinary Risk Factor Assessment and Management Programme for Hypertension (RAMP-HT).
Yu EY; Wan EY; Chan KH; Wong CK; Kwok RL; Fong DY; Lam CL
BMC Fam Pract; 2015 Jun; 16():71. PubMed ID: 26088560
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Hypertension Complications and Health Service Use 5 Years After Implementation of a Multicomponent Intervention.
Yu EYT; Wan EYF; Mak IL; Chao DVK; Ko WWK; Leung M; Li YC; Liang J; Luk W; Wong MMY; Ha TKH; Chan AKC; Fong DYT; Lam CLK
JAMA Netw Open; 2023 May; 6(5):e2315064. PubMed ID: 37223900
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of the multidisciplinary risk assessment and management program for patients with diabetes mellitus (RAMP-DM): a population-based cohort study.
Jiao F; Fung CS; Wan YF; McGhee SM; Wong CK; Dai D; Kwok R; Lam CL
Cardiovasc Diabetol; 2015 Aug; 14():105. PubMed ID: 26268736
[TBL] [Abstract][Full Text] [Related]
5. Five-Year Effectiveness of the Multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) on Diabetes-Related Complications and Health Service Uses-A Population-Based and Propensity-Matched Cohort Study.
Wan EYF; Fung CSC; Jiao FF; Yu EYT; Chin WY; Fong DYT; Wong CKH; Chan AKC; Chan KHY; Kwok RLP; Lam CLK
Diabetes Care; 2018 Jan; 41(1):49-59. PubMed ID: 29138274
[TBL] [Abstract][Full Text] [Related]
6. Effects of the Multidisciplinary Risk Assessment and Management Program for Patients with Diabetes Mellitus (RAMP-DM) on biomedical outcomes, observed cardiovascular events and cardiovascular risks in primary care: a longitudinal comparative study.
Jiao FF; Fung CS; Wong CK; Wan YF; Dai D; Kwok R; Lam CL
Cardiovasc Diabetol; 2014 Aug; 13():127. PubMed ID: 25142791
[TBL] [Abstract][Full Text] [Related]
7. Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals?
Saposnik G; Goodman SG; Leiter LA; Yan RT; Fitchett DH; Bayer NH; Casanova A; Langer A; Yan AT; ; ;
Stroke; 2009 Apr; 40(4):1417-24. PubMed ID: 19213947
[TBL] [Abstract][Full Text] [Related]
8. Management of hypertension and multiple risk factors to enhance cardiovascular health - a feasibility study in Singapore polyclinics.
Jafar TH; Tan NC; Allen JC; Pradhan SS; Goh P; Tavajoh S; Keng FM; Chan J
BMC Health Serv Res; 2016 Jul; 16():229. PubMed ID: 27391818
[TBL] [Abstract][Full Text] [Related]
9. Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction.
Hermida RC; Ayala DE; Fernández JR; Mojón A
Chronobiol Int; 2013 Mar; 30(1-2):68-86. PubMed ID: 23181592
[TBL] [Abstract][Full Text] [Related]
10. Role of time-of-day of hypertension treatment on the J-shaped relationship between blood pressure and cardiovascular risk.
Hermida RC; Ayala DE; Mojón A; Fernández JR
Chronobiol Int; 2013 Mar; 30(1-2):328-39. PubMed ID: 23181738
[TBL] [Abstract][Full Text] [Related]
11. Multicomponent intervention versus usual care for management of hypertension in rural Bangladesh, Pakistan and Sri Lanka: study protocol for a cluster randomized controlled trial.
Jafar TH; Jehan I; de Silva HA; Naheed A; Gandhi M; Assam P; Finkelstein EA; Quigley HL; Bilger M; Khan AH; Clemens JD; Ebrahim S; Turner EL; ; Kasturiratne A
Trials; 2017 Jun; 18(1):272. PubMed ID: 28606184
[TBL] [Abstract][Full Text] [Related]
12. Are polygenic risk scores for systolic blood pressure and LDL-cholesterol associated with treatment effectiveness, and clinical outcomes among those on treatment?
Tapela NM; Collister J; Liu X; Clifton L; Stiby A; Murgia F; Hopewell JC; Hunter DJ
Eur J Prev Cardiol; 2022 May; 29(6):925-937. PubMed ID: 34864974
[TBL] [Abstract][Full Text] [Related]
13. Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level--the "normotensive non-dipper" paradox.
Hermida RC; Ayala DE; Mojón A; Fernández JR
Chronobiol Int; 2013 Mar; 30(1-2):87-98. PubMed ID: 23039824
[TBL] [Abstract][Full Text] [Related]
14. Sleep-time ambulatory blood pressure as a prognostic marker of vascular and other risks and therapeutic target for prevention by hypertension chronotherapy: Rationale and design of the Hygia Project.
Hermida RC
Chronobiol Int; 2016; 33(7):906-36. PubMed ID: 27221952
[TBL] [Abstract][Full Text] [Related]
15. Management of risk factors among ambulatory patients at high cardiovascular risk in Canada: a follow-up study.
Elbarasi EA; Goodman SG; Yan RT; Tan MK; Hackam DG; Leiter LA; Langer A; Yan AT;
Can J Cardiol; 2013 Dec; 29(12):1586-92. PubMed ID: 24041994
[TBL] [Abstract][Full Text] [Related]
16. [Impact of the presence of cardiovascular disease on blood pressure and lipid control in the hypertense population attended in primary care].
Barrios Alonso V; Escobar Cervantes C; Calderón Montero A; Llisterri Caro JL; Echarri Carrillo R; Matalí A
Aten Primaria; 2008 Jan; 40(1):21-7. PubMed ID: 18190764
[TBL] [Abstract][Full Text] [Related]
17. Effect of Achieved Systolic Blood Pressure on Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Population-Based Retrospective Cohort Study.
Wan EYF; Yu EYT; Chin WY; Fung CSC; Fong DYT; Choi EPH; Chan AKC; Lam CLK
Diabetes Care; 2018 Jun; 41(6):1134-1141. PubMed ID: 29592967
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications.
Hermida RC; Ayala DE; Mojón A; Fernández JR
Chronobiol Int; 2013 Mar; 30(1-2):315-27. PubMed ID: 23181712
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial.
Zanchetti A; Liu L; Mancia G; Parati G; Grassi G; Stramba-Badiale M; Silani V; Bilo G; Corrao G; Zambon A; Scotti L; Zhang X; Wang H; Zhang Y; Zhang X; Guan TR; Berge E; Redon J; Narkiewicz K; Dominiczak A; Nilsson P; Viigimaa M; Laurent S; Agabiti-Rosei E; Wu Z; Zhu D; Rodicio JL; Ruilope LM; Martell-Claros N; Pinto F; Schmieder RE; Burnier M; Banach M; Cifkova R; Farsang C; Konradi A; Lazareva I; Sirenko Y; Dorobantu M; Postadzhiyan A; Accetto R; Jelakovic B; Lovic D; Manolis AJ; Stylianou P; Erdine S; Dicker D; Wei G; Xu C; Xie H; Coca A; O'Brien J; Ford G
J Hypertens; 2014 Sep; 32(9):1888-97. PubMed ID: 24979303
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
